In the BioHarmony Drug Report Database

"Preview" Icon

Adalimumab

Humira (adalimumab) is an antibody pharmaceutical. Adalimumab was first approved as Humira on 2002-12-31. It is used to treat ankylosing spondylitis, crohn disease, hidradenitis suppurativa, juvenile arthritis, and psoriatic arthritis amongst others in the USA. It has been approved in Europe to treat ankylosing spondylitis, arthritis, crohn disease, hidradenitis suppurativa, and juvenile arthritis amongst others. The pharmaceutical is active against tumor necrosis factor.

 

Trade Name

 

Humira
 

Common Name

 

adalimumab
 

ChEMBL ID

 

CHEMBL1201580
 

Indication

 

ankylosing spondylitis, arthritis, crohn disease, hidradenitis suppurativa, juvenile arthritis, papulosquamous skin diseases, psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, uveitis
 

Drug Class

 

Monoclonal antibodies

Image (chem structure or protein)

Adalimumab structure rendering